-
Rongchang's US$2.6 billion partnership ranks first, surpassing major pharmaceutical companies such as Roche and Daiichi Sankyo. Who will be among the top 10 ADC drugs in the world in 2021?
Time of Update: 2021-09-18
In 2019, Roche’s second ADC drug Polivy was approved for marketing by the FDA, combined with bendamustine and rituximab, for relapsed or refractory diffuse large B-cell lymphoma that had previously received at least 2 therapies (R/R DLBCL) patients .
-
Li Keqiang inspected and held a symposium with medical experts in Peking Union Medical College Hospital
Time of Update: 2021-09-18
Li Keqiang emphasized when inspecting and holding a symposium of medical experts in Peking Union Medical College HospitalLi Keqiang emphasized when inspecting and holding a symposium of medical exper
-
How can China's rare disease industry take the next step to crack the "sky-price drug" crisis?
Time of Update: 2021-09-18
Although with policy support, China has made great progress in the research and development of rare disease drugs in recent years, and more and more companies have entered this field, bringing new hope for the diagnosis and treatment of rare diseases .
-
Chia Tai Tianqing storms innovative drugs this year, 13 Class 1 new drugs approved for clinical trials
Time of Update: 2021-09-18
Source: CDE official website From September until now, CP Tianqing Pharmaceuticals has two Class 1 new drugs declared for clinical use, namely TQB2868 injection and TQB2916 injection.
-
Technical guidelines for clinical trials of modified new drugs for ADHD drugs and children's chemicals released
Time of Update: 2021-09-18
On September 13, CDE issued the technical guidelines for clinical trials of attention deficit hyperactivity disorder drugs and the technical guidelines for clinical trials of improved new drugs for chemical drugs for children, which will be implemented from the date of issuance .
-
The State Food and Drug Administration issued 63 medical device industry standards
Time of Update: 2021-09-18
On September 9, the State Food and Drug Administration website issued 63 medical device industry standards including YY 0671-2021 " Medical Devices Sleep Apnea Treatment Masks and Application Accessories" .
-
GlaxoSmithKline "Mepolizumab" is expected to be approved for listing in China in the near future
Time of Update: 2021-09-18
According to the announcement of the National Food and Drug Administration (NMPA) of China, the listing application status of the anti-IL-5 monoclonal antibody mepolizumab (mepolizumab) injection of GlaxoSmithKline (GSK) has been updated to "under approval".
-
Innovent and Bolt reached an agreement to jointly develop three anti-tumor drugs using antibody-immune stimulation coupling technology
Time of Update: 2021-09-13
(NASDAQ: BOLT) (hereinafter referred to as "Bolt"), a biotechnology company in the clinical stage, has created an effective binding antibody Targeting precision and new immunotherapies for the innate and adaptive immune systems have jointly announced today that the two parties have reached a new drug research and development agreement to jointly develop three antibody-immunostimulatory conjugate (ISAC) candidate drugs for the treatment of tumors .
-
The fifth round of national procurement, implementation time announced
Time of Update: 2021-09-13
HenanHenan On August 31, the Henan Provincial Medical Security Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fifth Batch of National Organized Drug Centralized Procurement and Chongqing Pharmaceutical Procurement Alliance to ensure supply, stable price and quantity procurement .
-
Japan approves Merck's Keytruda to treat breast and colorectal cancer
Time of Update: 2021-09-13
In the randomized, placebo-controlled phase 3 KEYNOTE-355 (NCT02819518) trial, compared with the placebo combined chemotherapy group, the risk of disease progression or death in the Keytruda combined chemotherapy group was significantly reduced by 35%, and progression-free survival (PFS) Showing a statistically significant and clinically significant prolongation (9.
-
Takeda Vonolasen is about to be approved for new indications, P-CABs intensify competition in the domestic acid suppressant market
Time of Update: 2021-09-13
In February 2015, the drug was approved in Japan for the treatment of acid-related diseases, including reflux esophagitis, gastric ulcer, duodenal ulcer, and prevention during treatment with low-dose aspirin or non-steroidal anti-inflammatory drugs Recurrence of gastric ulcer or duodenal ulcer and eradication of Helicobacter pylori were launched in South Korea in July 2018 .
-
Nuocheng Jianhua will bring its innovation pipeline to the 2021 Service Trade Fair to help healthy China
Time of Update: 2021-09-13
ST5011), With the theme of "science-driven innovation, patient needs-oriented" as the exhibition theme, Nuocheng Jianhua will exhibit the national "major new drug creation" special achievement -the new Bruton's tyrosine kinase (BTK) inhibitor abutinib, And other pipelines of innovative drugs under development .
-
FDA releases draft guidelines for alternative dosing regimens for PD-1 and PD-L1 cancer immunotherapy
Time of Update: 2021-09-13
S. FDA issued on August 25 the draft guidelines of "Pharmackinetic-based Standards Supporting Alternative Dosing Schemes of PD-1 or PD-L1 Blocking Antibodies for the Treatment of Cancer Patients" to help sponsors "seeking and Approval of different alternative intravenous (IV) dosing regimens tested in clinical efficacy and safety trials" .
-
Inventory of sales expenses of 15 multinational pharmaceutical companies in the first half of the year: the highest is more than 10 billion, and the proportion is declining year by year.
Time of Update: 2021-09-13
There is no doubt that although AstraZeneca’s overall sales expenditures accounted for the highest proportion of revenue among multinational pharmaceutical companies, data in recent years have clearly pointed out that its proportion has declined rapidly.
-
Columbotai: The third generation of Claudin 18.2 ADC reported to the clinic
Time of Update: 2021-09-13
(Source: CDE official website) SKB315 is a third-generation antibody conjugate drug (ADC) targeting Claudin 18.
It includes Sichuan Kelun Pharmaceutical Co.
, Sichuan Kelun Pharmaceutical Research Institute Co.
Sichuan Kelun Botai Bio-Pharmaceutical Co.
(Product pipeline source: Klus Pharma Inc.
-
Cinda is showing off!
Time of Update: 2021-09-13
In addition, the listing application of Sintilimab injection for second-line squamous non-small cell lung cancer is under review and is expected to be approved by the end of 2021 .
With the expansion of production capacity, the approval of new indications and the development of overseas markets, Sintilimab's sales are expected to increase .
-
Nature's in-depth review: Where will the new generation of mRNA therapy go?
Time of Update: 2021-09-13
A few days ago, a review published by Nature Reviews Materials made a detailed inventory of the development of LNP technology for mRNA delivery, and discussed the broad clinical application prospects and challenges that need to be solved for this technology in addition to infectious disease vaccines.
-
The market value has doubled: why the pioneering pharmaceutical industry is flying against the wind
Time of Update: 2021-09-13
Due to the discovery that a prostatic drug under research, Prokalamide, may have a potential effect on the treatment of new crowns, the share price of Chinese biotechnology company Kaiyuan Pharmaceutical in Hong Kong stocks has doubled several times, and its market value has soared from HK$6.
-
CStone Pharmaceuticals releases semi-annual financial report: two new drugs will be approved soon for commercialization into the fast lane
Time of Update: 2021-09-13
In order to promote the successful launch of products, CStone Pharmaceuticals has expanded the coverage of the drug market by cooperating with medical service providers, regulatory agencies, hospitals, pharmacies, insurance companies, and other groups in the medical industry.
-
Japan: Impurity particles in American Modena vaccine are visible to the naked eye. 1.63 million doses are suspended
Time of Update: 2021-09-13
A few days ago, the Shiji News Agency said that a total of about 570,000 doses of Modena vaccine were found to contain impurities.